18P Targeting MET-expressing NSCLC with a VNAR-based theranostic agent

ESMO Open 2026 Open access

Read full text
Authors: J. West, Rachel L. Minne, Kwangok P. Nickel, Gihan S. Gunaratne, R. Hernandez, Andrew M. Baschnagel, Randall J. Kimple, A. Lebeau
DOI: 10.1016/j.esmoop.2026.106121
Cited by: 1

Abstract

Non-small cell lung cancer (NSCLC) comprises 85% of lung cancer cases and is the leading cause of cancer death in the U.S. Many NSCLC patients have genomic alterations that can be selectively targeted by molecular therapies. The MET receptor has key roles in cell proliferation and wound healing, and is altered in 3-4% and amplified in 3-6% of patients. While two tyrosine kinase inhibitors are approved for such patients, resistance inevitably develops. Novel treatment options for resistant patients are urgently needed.

Fields of Study & Subjects

Liver physiology and pathology Fibroblast Growth Factor Research Cancer Stress Anesthesia and Immune Response

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106121–106121
Publication date
1 April 2026
Language
EN